Like all medicines, Ubivit LC Tablet 10s may cause side effects in some individuals
Clinical trials reveal interesting differences: individuals without diabetes (in SURMOUNT trials) achieved weight loss of up to 22.9%, whereas those with diabetes (SURPASS studies) experienced more modest weight loss, as the trials primarily focused on blood sugar control
The jump from diabetes treatment to weight management was not a change in formulation, but rather an increase in dose
The Phase 2 study directly referenced the SURMOUNT-1 comparator when discussing clinical meaning
If your primary goal is fat loss, stick with LCLT
If semaglutide isn't delivering expected results after 812 weeks, PlexusDx practitioners can transition you to tirzepatide (a dual GIP/GLP-1 agonist) or GLP-Squared, the dual-compound formulation combining both agents